Larimar Therapeutics appoints John Harlow as President and COO

Larimar Therapeutics announced the appointment of John Harlow as President and Chief Operating Officer, effective September 29, 2026. The company says the move aims to strengthen commercial, operational and business development capabilities as it advances its pipeline, including a therapy called nomlabofusp toward potential approval.

What happened

Larimar Therapeutics, a Nasdaq-listed biotechnology company, announced a leadership change. John Harlow was appointed as President and Chief Operating Officer (COO), reporting to the Chief Executive Officer, Carole Ben-Maimon, M.D. The appointment is effective September 29, 2026. The company describes Harlow as bringing more than 25 years of experience in commercial operations and business development in biopharma. Says his leadership will help translate strategy into execution as the company advances its clinical program, including nomlabofusp toward potential regulatory approval.

Who is affected

The change affects Larimar’s executive leadership team and, more broadly, its investors and potential patients who rely on the company’s experimental therapies. Investors may look to leadership stability as part of the company’s ongoing development plans. Employees and partners within Larimar’s commercial, clinical and business development divisions may experience shifts in leadership focus and strategy as they adapt to the new COO’s guidance.

Practical next steps

For stakeholders tracking the company, monitor Larimar’s regulatory and clinical updates, especially around nomlabofusp’s progress toward potential approval. Review company press releases and regulatory filings for details on how leadership changes may influence timelines, partnerships or strategic priorities. If you are an investor, consult your financial advisor about how executive leadership moves fit with your risk tolerance and investment horizon.

Limits and questions

The announcement provides limited detail beyond the appointment and general description of Mr. Harlow’s background. Specific impacts on product development timelines, clinical trial results, or regulatory submissions are not described. Readers should rely on official Larimar communications for precise implications of the leadership change.

Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.